Trials / Completed
CompletedNCT05585398
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
A Phase 1 Single-center Study to Evaluate the Distribution of NT 201 Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different delivery methods (conventional needle and microneedles).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IncobotulinumtoxinA | Intradermal injections using different delivery methods (conventional needle and microneedles) |
Timeline
- Start date
- 2022-10-19
- Primary completion
- 2023-02-24
- Completion
- 2023-04-13
- First posted
- 2022-10-18
- Last updated
- 2023-06-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05585398. Inclusion in this directory is not an endorsement.